In a recent OncLive Peer Exchange, Dr. Gregory Vidal partnered with a panel of breast oncology experts to discuss the standard-of-care treatment approaches for early-stage HR-positive/HER2-negative breast cancer.
– Evolution of HER2-negative management
– Updates in HR-positive treatment
– Importance of genetic testing
– Utilization of endocrine therapy
– BRCA mutations
Click here to watch the full video discussion and/or read the conversation transcript.